[Phase II study of combination of gemcitabine and carboplatin in advanced non-small cell lung cancer (an interim report)].

Abstract

A phase II study of combination therapy with gemcitabine and carboplatin was performed in 24 patients with advanced non-small cell lung cancer to evaluate the efficacy and safety of the therapy. Patients were treated at 3-week intervals with two courses or more of the regimen consisting of gemcitabine 1,000 mg/m(2) and carboplatin AUC 2 on day 1 and day 8. Response rate was 37.5% (9/24) (95% confidence interval: 18.8-59.4%). The median number of courses was 3(range 1-8). The time to progressive disease was 147 days and the median survival was 338 days. The one-year survival rate was 45.8%. The major toxicity was hematotoxicity, and >or=grade 3 neutropenia(58.3%)and thrombocytopenia (45.8%) occurred. None of >or=grade 3 non-hematotoxicities were evident, but grade 2 rash (8.3%) and fever (8.3%), nausea (4.2%), vomiting (4.2%) occurred. None of the other severe toxicities appeared. In conclusion, this combination therapy was suggested to be tolerable with a high response rate and safety, and we plan to continue testing.

• Authors: Kiyoshi Mori, Yukari Kamiyama, Tetsuroh Kondoh, Tetsuroh Kodama
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 35 Issue 6 Pg. 931-5 (Jun 2008) ISSN: 0385-0684 [Print] Japan
• PMID: 18633219 (Publication Type: Clinical Trial, Phase II, English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Deoxycytidine
• Carboplatin
• Gemcitabine

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
• Carboplatin (administration & dosage, adverse effects, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy, pathology)
• Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Female
• Humans
• Lung Neoplasms (drug therapy, pathology)
• Male
• Neoplasm Staging
• Gemcitabine